ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541) is trading at HK$3.13, about ₹39 at today's HKD/INR rate, as of 9 Oct 2026, 4:08 AM ET, down 1.26% today. Indian residents can buy ImmuneOnco Biopharmaceuticals (Shanghai) from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$3.05
Today's high
HK$3.20
52 week low
HK$2.80
52 week high
HK$14.59
1541 opened at HK$3.17, closed previously at HK$3.17, and has traded between HK$2.80 and HK$14.59 over the past 52 weeks.
About
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Key statistics
Avg. volume
1.16M
Market cap
HK$1.31B
P/E Ratio
-5.03
Price-to-sales ratio
7.39
Enterprise value
CN¥1.71B
Free cash flow yield
-9.13%
Debt-to-equity ratio
0.58
Return on equity
-26.89%
ROIC
-21.33%
Beta
0.20
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥150.30M
Earnings per share
-CN¥0.51
Free cash flow
-CN¥197.13M
Net profit margin
-151.13%
Gross margin
94.57%
EBITDA
-CN¥203.03M
Revenue growth
102.70%
Similar securities
This is not an investment recommendation
How to buy ImmuneOnco Biopharmaceuticals (Shanghai) from India
Indian residents can buy ImmuneOnco Biopharmaceuticals (Shanghai) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers. Read the full guide: how to invest in ImmuneOnco Biopharmaceuticals (Shanghai) from India
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for ImmuneOnco Biopharmaceuticals (Shanghai) and place an order
Find ImmuneOnco Biopharmaceuticals (Shanghai) by name or by its ticker, 1541, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. ImmuneOnco Biopharmaceuticals (Shanghai) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your ImmuneOnco Biopharmaceuticals (Shanghai) position in HKD and INR. ImmuneOnco Biopharmaceuticals (Shanghai) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Trading and taxes when buying ImmuneOnco Biopharmaceuticals (Shanghai) from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneImmuneOnco Biopharmaceuticals (Shanghai) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
FAQs
Can Indian residents buy ImmuneOnco Biopharmaceuticals (Shanghai) stock?
Yes. ImmuneOnco Biopharmaceuticals (Shanghai) (1541) has been listed on the Hong Kong Stock Exchange since 2023, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one ImmuneOnco Biopharmaceuticals (Shanghai) share cost in rupees?
One ImmuneOnco Biopharmaceuticals (Shanghai) share is HK$3.13 — about ₹39 at an HKD/INR rate of 12.34 on 8 Oct 2026. Both the ImmuneOnco Biopharmaceuticals (Shanghai) price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying ImmuneOnco Biopharmaceuticals (Shanghai) from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of ImmuneOnco Biopharmaceuticals (Shanghai)?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on ImmuneOnco Biopharmaceuticals (Shanghai) shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the ImmuneOnco Biopharmaceuticals (Shanghai) price. Paasa issues a capital-gains statement for your return.
Does ImmuneOnco Biopharmaceuticals (Shanghai) pay a dividend?
No. ImmuneOnco Biopharmaceuticals (Shanghai) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade ImmuneOnco Biopharmaceuticals (Shanghai) from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is ImmuneOnco Biopharmaceuticals (Shanghai) a Hong Kong SAR China company, and does that change how it is taxed?
ImmuneOnco Biopharmaceuticals (Shanghai) trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. ImmuneOnco Biopharmaceuticals (Shanghai) trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare ImmuneOnco Biopharmaceuticals (Shanghai) shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your ImmuneOnco Biopharmaceuticals (Shanghai) holding, its cost and its closing value.
How do I sell ImmuneOnco Biopharmaceuticals (Shanghai) and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.